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Abstract: This review aimed to gather the available literature investigating the effects of probiotics
against the most common viral infections using in vitro trials in cell lines and in vivo clinical tri-
als in both experimental animals and humans. Probiotics were employed to prevent and reduce
symptoms of infections caused by common viruses, especially respiratory tract viruses, but also for
viral digestive infections (such as rotavirus, coronavirus, or norovirus) and other viral infections
(such as viruses that cause hepatitis, human papillomavirus, human immunodeficiency virus, and
herpes simplex virus). Different probiotics have been studied to see their possible effect against the
abovementioned viruses, among which different Lactobacillus species, Bifidobacterium, Clostridium,
Enterococcus, and Streptococcus can be highlighted. In many cases, mixtures of various probiotic
strains were used. Although the results obtained did not show similar results, in most cases, probiotic
supplementation improved both barrier and biochemical immune responses, decreased susceptibility
to viral infections, and enhanced the effects of concomitant vaccines. Works collected in this review
show a beneficial effect of probiotics in the prevention and treatment of different viral infections. We
found interesting results related to the prevention of viral infections, reduction of the duration of
diseases, and decrease of symptoms.
Keywords: probiotic; gut microbiota; viral infection; viruses; influenza
1. Introduction
The mammalian intestine is a complex ecosystem, as it is a point of symbiosis be-
tween the host and approximately 1014 types of resident microorganisms, which have been
acquired even before birth and continue to exist throughout life [1]. This community of
microorganisms is often called gut microbiota (GM) [2,3]. The microbiome includes the
microorganisms and their genetic material, which importantly contributes to host physi-
ology by providing genetic elements that are not already present in the host genome [4].
Among GM microbes, some species can confer beneficial effects to the physiology and
metabolism of the host. Among them, the Food and Agriculture Organization of the United
Nations [5] defined the term probiotic as “live microorganisms, which when consumed
in adequate amounts, confer a health effect on the host.” Probiotics are live bacteria that
can be given as a supplement or in a food product that, if ingested in an adequate amount,
can provide benefits to the host. Probiotics are composed mainly of lactic acid bacteria
(LAB) and complex carbohydrate fermenters, which are part of the normal GM of humans
and animals. Supplementation with probiotics can provide benefits to the host directly
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by preventing infection, or indirectly by enhancing the immune response of the host.
There is scientific evidence that consumption of probiotics can play a role in increasing
defense against external pathogens, thus maintaining the balance of the intestinal immune
system [6,7].
Viral infectious diseases nowadays have a great impact on humankind. Viral infections
produce variable morbidity and mortality, negatively affecting community health and
causing wide economic losses [8]. The best example of this global threat may be the
infectious disease caused by the new Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2), which during the 2019–2020 pandemic has infected millions of people
worldwide [8]. Consequently, it is important to find alternative and safe ways to prevent
viral infections and reduce the morbidity and mortality of viral infections. Even partially
effective therapies for the treatment and prevention of viral infections can reduce the
mortality, morbidity, and economic losses caused by these infections [9].
A large number of antiviral drugs that may be effective in certain infections are now
available; however, the appearance of new viral strains through mutations is a major
threat. Although combination therapies of drugs are effective against several viral diseases,
it is always desirable to have additional approaches that may be used as preventives
or supplemental therapies [10]. Among different strategies to prevent and reduce viral
infections, adequate nutrition, including nutrients or food ingredients that enhance and
potentiate immune response, are useful alternatives to reduce the number of infections and
their severity. One nutritional strategy used in recent years to improve human immunity
and reduce the ability to be infected is the intake of probiotics [11].
The main objective of this work was to provide a literature review of the effects of
probiotic agents in the prevention and reduction of the severity of symptoms in viral
infections, with special emphasis on the most recently published works.
2. Probiotics and the Immune System
According to the FAO consensus [5], criteria for probiotic bacteria include that the
bacterial strain: (1) Must be able to survive in the gastrointestinal tract and proliferate
in the intestine; (2) must benefit the host through growth or activity in the human body;
(3) must be non-toxic and non-pathogenic; (4) must provide protection against pathogenic
microorganisms that employ multiple mechanisms; and (5) must lack transferable antibiotic
resistance. Bacterial strains of the same genus and species can have completely different
effects on the host. Given this, the search for probiotic agents has evolved, and now it is
even feasible to modify probiotics with increasingly complex functionalities by transferring
mobile genetic elements [12]. Because probiotics can possess antiviral activity, they can be
chosen as alternatives to or complementary antiviral therapies [13]. Although nowadays
there is a significant demand for bioactive components such as probiotics in Western
countries, consumers are reluctant to change their dietary habits [14]. Although in some
cases probiotic products were developed by pharmaceutical industry, they have become
increasingly popular among the public due to their inclusion in functional foods, generating
wider acceptance among consumers [15]. This suggests that there is great potential for
foods that are consumed regularly when they are converted to functional foods [14], that
show better consumer acceptance than pharmacological presentations.
The most common genus of microbes used as probiotics are LAB, such as Lactobacil-
lus [1], and primary oligosaccharide fermenters such as Bifidobacterium [16], although
other genera, and even yeast, such as Saccharomyces, were proposed and used as probiotic
agents [1]. One mechanism that probiotic strains, known as immunobiotics, can provide to
human or animal health is modulating the mucosal and systemic immune systems [17,18],
thus protecting against infectious diseases, including viral infections [13,19].
The consumption of probiotics has different beneficial effects on human health such
as the production of antimicrobial and anti-adhesion substances against pathogens, thus
facilitating the modulation of the immune system [20]. Probiotic bacteria can also inhibit
the adhesion of the invading virus to the host-cell receptor by binding to it [13]. Moreover,
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probiotics can exert antiviral activity by direct probiotic-virus interaction, production of
metabolites with antiviral inhibitory activity, or by stimulating the immune system of the
host [13]. Probiotics may indirectly interfere with the virus by altering the state of cells,
stimulating innate and adaptive immunity, or enhancing or suppressing associated molec-
ular signaling pathways [21]. Probiotic bacteria can also have a protective effect against
virus particles competing for adhesion to the cell surface. This has been tested in vitro and
reported as a useful mechanism for cell protection in case of mucosal virus infections [22].
Another way of actuation of probiotics is the regulation of innate immunity using toll
receptors and different signaling pathways, thus reducing inflammatory processes [23].
This regulation in innate immune system of the host can be kept increasing phagocytic
activity, the activity of leukocytes (polymorphonuclears and monocytes), the expression
of some receptors that are associated with phagocytosis, and the microbicidal function
of neutrophils [13]. Different scientific studies showed that viruses, when they enter the
body, activate an innate immune response where the inflammasomes are responsible for
destroying the pathogens. The immune system detects pathogens in multiple ways, and
there are two first-line of defense systems against viruses: The production of Type I inter-
ferons and interleukins (IL) IL-1β and IL-18 by inflammasomes. On the one hand, type I
interferons promote an antiviral state in the infected host, and on the other hand, cytokines,
including IL, induce inflammatory processes and modulate immune responses, produc-
ing antiviral effects [24]. For this reason, probiotic bacteria can regulate the activation of
the inflammasome in organisms that have previously suffered inflammation due to viral
infections. [24].
Another beneficial effect of probiotics is their capacity to help mature and activate
the mucosal immune system by secreting metabolites such as organic acid, short chain
fatty acids (SCFA), hydrogen peroxide, coagulation molecules, and bacteriocins, which are
antimicrobial compounds [25,26]. These metabolites, particularly SCFAs, influence the gut
epithelial and immune cells directly, enhancing the immune response. It was demonstrated
that SCFAs reduced pattern recognition receptor (PRR) stimulation through activation
of activated B-cell nuclear factor kappa-light-chain-enhancer and tumor necrosis factor-
alpha (TNFα) [27]. In in vitro alveolar macrophages, it has been seen that the induction
of low-level synthesis of nitric oxide can also influence the protective action of probiotic
bacteria against viruses in respiratory cells [28]. Many studies have demonstrated that
probiotics can increase the CD4+ lymphocytes count and regulate TNF-α, IL-6, IL-8, IL-10,
and IL-12 [26].
3. Major Viruses Involved in Human Diseases
Nowadays, there are up to 200 species of viruses that can infect humans, and their
number is increasing at a rate of 3–4 per year [29]. Consequently, most new human
pathogens are viruses, and it is common for the virus to be of animal origin. A substantial
proportion of mammalian viruses may cross the species barrier reaching humans. However,
only a small number of these have human-to-human transmission and are therefore capable
of causing human outbreaks. It will be practically inevitable that new human viruses will
continue to emerge, and thus, an effective global surveillance system for new viruses is
needed [29].
Although viruses can cause a wide variety of infections in different organs and sys-
tems of the human body, viruses were split, for this literature review, into three groups:
Respiratory viruses, digestive viruses, and other viruses. Acute viral respiratory infections
are among the leading causes of death worldwide, accounting for more than 4 million
deaths per year [11]. In addition, these viruses are a leading cause of pediatric morbidity
and mortality worldwide because of the immature immune system of the babies. On the
other hand, the elderly are more susceptible to serious complications due to their weakened
immune system [11].
These viruses spread easily between humans due to airborne transmission through
aerosols, causing outbreaks that are very difficult to control [30]. Viral respiratory pathogens
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belong to various virus families, so RNA-containing viruses are more significant: Picor-
naviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Coronaviridae, and DNA-containing
viruses, such as Adenoviridae and Parvoviridae [11,31]. Individuals can also be infected
simultaneously with multiple viruses, and in some cases, multiple viruses have synergistic
effects against host health [11,27].
Regarding viral gastrointestinal infections, different viruses, such as rotavirus (RV),
norovirus (NV), or calicivirus (CV; including the agent Norwalk and astrovirus), can infect
the human gastrointestinal tract and are responsible for many illnesses related to childhood
diarrhea and gastroenteritis outbreaks worldwide [20]. These viruses have uncoated RNA,
which makes them highly infectious and are transmitted in a fecal-oral manner. These
infections are usually mild to moderate in severity and short in duration [32]. Rotavirus was
traditionally the most common cause of severe dehydrating diarrhea in children, estimated
to cause approximately 200,000 deaths in children under five years of age each year [19].
After the large-scale implementation of RV vaccines, NV is now the leading cause of severe
diarrhea in children in developed countries and is also considered the most common
cause of foodborne illness, nowadays associated with approximately 18% of gastroenteritis
cases worldwide [32]. Astroviruses account for 2–9% of pediatric gastroenteritis cases
worldwide [32]. There are enteric viruses that replicate in the gastrointestinal tract but are
asymptomatic, such as reovirus or poliovirus, that can cause severe disease after spreading
to peripheral tissues [32].
Another important group of viral infections affecting humans worldwide are liver
infections. Among them, enterically-transmitted Hepatitis A (HAV), Hepatitis B virus
(HBV), Hepatitis C virus (HCV), and Hepatitis E (HEV) viruses are causes of acute viral
hepatitis in humans [33,34]. These viruses are transmitted through various routes, such
as blood transfusions, sexual contact, and consumption of water or food contaminated
by feces. HAV use the latter route for transmission; therefore, their outbreaks are more
common in underdeveloped countries [35].
Skin viral infections include a large variety of viral agents, among which herpes
zoster, which is caused by the reactivation in adults of the varicella-zoster virus, stands out.
Herpes viruses can cause a primary infection, establish a latent infection in a specific set
of cells in their host, and then reactivate when immunity weakens [36]. One of the most
common members of the herpes virus family is cytomegalovirus (CMV), and more than
80% of primary infections occur in transplants. Herpes simplex virus (HSV) mainly affects
the genital and perioral regions [36]. Another virus that causes human skin infections is the
human papillomavirus (HPV), which presents several different types of warts, depending
on the infected surface and its relative humidity, and pressure patterns [37]. Human
papillomavirus represents a diverse group of viruses that primarily infect epithelial and
mucosal tissues [38]. Polyomaviruses have been suspected as potential etiological agents in
human skin cancer. These viruses infect epithelial tissues throughout the body, producing
benign and malignant lesions, including common and genital warts [39].
Concerning viruses that can cause neurological infections, rabies virus (RABV) is one
of the diseases that has been known since the beginning of civilization and has caused
much fear. According to the World Health Organization [40], more than 59,000 and 21,476
deaths have been recorded worldwide and in Africa, respectively, due to this virus. Rabies
is a disease of zoonotic origin caused by neurotropic viruses and is mostly spread by rabid
animals, belongs to the genus lyssavirus, family Rhabdoviridae [41]. Other viral neurological
infections are caused by arboviruses, which include several families of viruses that are
transmitted by arthropod vectors. The arbovirus group includes Flaviviridae, Togaviridae,
Bunyaviridae, and Reoviridae families that possess a high capacity to adapt rapidly to
changing environmental and host conditions [42]. On the other hand, the most common
cause of epidemic viral encephalitis in the United States today is West Nile virus infection.
The incidence of this virus has increased significantly since 2008, especially in southern
Europe. This and other mosquito-borne flaviviruses are considered endemic in Europe,
such as Usutu virus [43].
Foods 2021, 10, 130 5 of 20
There are also a large variety of hematological viruses, which cause infections with
hemorrhagic fevers, that are RNA viruses encased in a lipid bilayer derived from the host′s
cell membrane [44]. Viral hemorrhagic fevers are typically endemic in some regions, can
cause large outbreaks, and have high mortality rates. They are characterized by an acute
febrile syndrome with hemorrhages and affect both humans and animals [44,45].
4. Probiotic Usage against Respiratory Viruses
It has been demonstrated that the intestinal microbiota affects the health of the lungs
due to the direct relationship between the microbiota and the lungs, known as the “gut-lung
axis”. This axis is bidirectional, so endotoxins and microbial metabolites can affect the lung
through the blood, and on the other hand, when inflammation takes place in the lung it
can affect the intestinal bacteria [23]. Previous studies have found respiratory infections
that are related with a change in the composition of the GM [23]. For example, mice
with influenza viral infections in their respiratory tract have increased Enterobacteriaceae
and reduced Lactobacillus and Lactococcus in their GM [46]. Secreted metabolites and
immunomodulatory signals, such as secondary bile acids, secreted by commensal bacteria
bind to their receptors in innate cells, such as macrophages, stimulating their metabolism
and functions [23]. Additionally, it was demonstrated in murine models that removing
some bacterial species from the GM by antibiotic treatments leads to an increased risk of
influenza virus [46].
Disrupting the adhesion of the virus to mucosal cells could be beneficial to the host.
Probiotic bacteria could bind directly to the virus, producing this disruption [25]. However,
despite the abovementioned results about probiotic bacteria in the prevention and treatment
of respiratory viral infections, nowadays there is no clear consensus about this matter,
because on the one hand there are clinical trials that demonstrate the benefit of the use of
probiotics in respiratory infections, but other clinical trials did not obtain any advantage
after probiotic bacteria usage.
An important meta-analysis, with more than 8000 preterm infants included in several
clinical trials, demonstrated that patients receiving enteral supplementation with probiotics
showed a reduction in mortality caused by respiratory infections [47]. Viruses are especially
important in respiratory tract infections because they cause more than 90% of upper
respiratory tract infections [48]. The previous works regarding the effect of probiotic
supplementation on viral respiratory infections is shown in Table 1. In most cases, the
trials investigating this relationship were performed in mouse models [49–63], but some
were also in clinical trials with children [64–68], adults volunteers [9,69–77], and the
elderly [78,79]. The probiotic bacteria employed to prevent respiratory viral infections, in
most cases, were Lactobacillus strains. However, other bacterial genera were also employed,
such as Clostridium [69], Bacillus [69], Enterococcus [69], Bifidobacterium [25,65,67,68,77,80],
Streptococcus [81], and Propionibacterium [67].
The lack of consensus on probiotic strains/gender may be due to differences in
studies conducted and outcomes reported measures, the length of intervention, study
populations used (children vs. adults), bacterial dose (106–1010 CFU/day), or different
matrices (milk, yogurt, capsules) used. Additionally, decreased immunity due to aging may
partly explain the conflicting results in the elderly [9]. For instance, it was demonstrated
that specific strains of lactobacilli could bind and inactivate flu-like respiratory virus
in vitro [9]. Probiotic lactobacilli were reported to protect against respiratory tract infections
by modifying innate and acquired host immune responses [50]. Additionally, a concrete
lactobacilli strain (L. plantarum DK119) can prevent influenza A H1N1 and H3N2 infections
and mortality in a mouse model, promoting innate host immunity to influenza infection by
modulating alveolar macrophages and dendritic cells [51].
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Table 1. Effects of probiotics against respiratory viruses.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference
In vivo using female
BALB/c mice
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(LAB)
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Table 1. Cont.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference
Clinical trial in 233





L. paracasei 3.6 x 109
CFU, three bottles per




The intake of yogurt
containing L. paracasei
could protect against the
risk of acute upper
respiratory tract infection
in the mid-aged and















3 × 107 CFU/mL,
L. casei at
3 × 107 CFU/mL, and
L. fermentum at
3 × 106 CFU/mL or








levels of serum INF-g











gavaged (200 µL) with
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cells in the lungs after
L. paracasei gavage and
before influenza infection
[54]














1.25 × 1010 CFU of
probiotics plus 50 mg
vitamin C or a placebo









Clinical trial in 1000
volunteers
Lactobacillus casei
DN-114 001 200 g/day for 3 months
Respiratory common
infectious diseases









1 × 109 CFU/day for 1
to 30 days and





A and B, Human
metapneumovirus,
parainfluenza 1, 2, and 3,





infections was lower in
the probiotic group. The
incidence of rhinovirus




episodes tended to be
lower in the prebiotic but
not in the probiotic group
[66]
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Table 1. Cont.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference
Clinical trial in 629
otitis-prone children






8-9 × 109 CFU/day for
6 months
Human bocavirus 1-4 and
rhinovirus/enterovirus
Lower number of human
bocavirus 1 positive
sample during the study,












This study shows that B.
animalis subsp. lactis has
no effect on the
prevention of respiratory
tract infection in children.
There was no significant
difference in the number
of people infected or in
the duration of infection
in the intervention group
and the placebo group
[68]
Clinical trial in 97
daycare children L. rhamnosus GG





influenza A, and PIV 1-2
Respiratory symptoms
decreased in children per
month, but there was no
effect on the occurrence
of respiratory viruses
[82]
Clinical trial in 192
adults
L. rhamnosus GG + B.
lactis BB-12
5 × 109 CFU of GG and
2 × 109 of




RSV A and B, adenovirus,
coronavirus (229E/NL63
and OC43/HKU1),





after 3 months, but no




Clinical trial in 209
adults L. plantarum DR7









Two clinical trials in
86 and 222 elderly
volunteers
L. casei DN 114 001 Dairy drink (Actimel
®)
for 7 and 13 weeks
Influenza A (H1N1 and
H3N2) and B
Daily consumption of





over 70 years of age
[79]








106 CFU/mouse for 3, 6,





L. rhamnosus increases the
production of IgA in the
secretion of the mucosa
and the activity of T cells




Clinical trial in 42
healthy adults L. rhamnosus GG
Capsules containing
1 × 1010 CFU twice
daily for 28 days
Influenza A (H1N1 and
H3N2) and B
On day 28, a significant
increase in seroprotection
in the LGG group for the
H3N2 vaccine strain was
found
[75]
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Table 1. Cont.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference
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[76]
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Table 1. Cont.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference
Clinical trial in 211
subjects
B. animalis ssp. lactis
BB-12(DSM15954),
L. paracasei ssp.



















L. gasseri at 1× 108 or
1.6× 109 CFU/mouse/day
for 21 days
Influenza A virus (PR8)
Oral administration of
L. gasseri improved the
survival rates and the
titer of the virus in the
lungs, thus making the
mice stronger against a
viral infection
[62]






every day at a dose of









Genera other than Lactobacillus were employed as probiotic mixtures and not individ-
ually. In most cases, probiotics were applied against influenza virus infections, with the
exceptions of Kumpu et al. [64], Luoto et al. [66], and Garaiova et al. [65], who investigated
various viruses, Berggren et al. [70], who investigated probiotic effects against cold infec-
tions, and Guillemard et al. [73], who investigated effects against rhinopharyngitis. It is
normal that the effects against influenza viruses have been the most investigated virus be-
cause the influenza virus produces a respiratory infection that is a major cause of morbidity
and mortality worldwide, and new influenza subtypes become more dangerous to society.
Studies have shown that oral and intranasal administration of LAB protects against this
virus. In addition, LAB, such as certain species of Lactobacillus and Bifidobacterium, have
been reported to modulate systemic and mucosal immune responses, mainly by improving
mucosal Immunoglobulin A (IgA) production [49].
Additionally, due to the SARS-Cov2 pandemic, the effects of probiotics against this
disease were recently investigated. One of the serious clinical manifestations of COVID-19,
especially in the elderly and immunosuppressed, is pneumonia and the severity of acute
respiratory distress syndrome [83], children suffer less severe symptoms [84]. Thus, it
is reasonable to think that improving innate immunity could be useful in reducing the
severity of this infection.
5. Probiotic Usage against Digestive Viruses
It is well known that some probiotics can prevent infections in the gastrointestinal
tract and infections in other organs [48]. The main viruses that are involved in human
diarrhea are rotavirus (RV), calicivirus (CaV; which includes norovirus (NV) and sapovirus
(SAP)), enteric adenovirus, and astrovirus. Of these, RV and CaV are responsible for most
cases of severe gastroenteritis [2]. RV is transmitted through contact between humans and
responsible for one-third of the cases of severe diarrhea in children under five years old
around the world [2]. Enteric viruses can be classified into two different mechanisms. One
type multiplies in the intestinal epithelium, such as RV, which cause gastroenteritis, and the
other type multiplies in the intestine, such as enteroviruses, but spreads to target organs,
causing serious diseases [2].
In recent years, it has been shown that several LAB strains exert protection against
infections produced by enteric viruses, increasing the production of specific antibodies
and shortening the episodes of diarrhea [85,86]. Among its protective effects produced
are mechanisms, such as increased immune defenses of the host and the production of
antibiotic-like substances, IgA, and cytokine stimuli [86]. These probiotic strains have also
been shown to increase mucosal secretions, improve intestinal motility, or enhance the
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productions of SCFA that act as protectors for the gut. There are also studies indicating
that probiotic bacteria may have effects on the maturation of intestinal macrophages and
dendritic cells and enhance cytokine production [86].
Table 2 shows different studies on the effect of probiotics and prebiotics against viruses
that cause digestive diseases. These studies have been carried out both in vitro using cells
lines [6,7,85,87,88] and in vivo using mouse models [80,89,90] and humans [91,92]. For these
purposes, single Lactobacillus [88,90] or Bifidobacterium [80], but more frequently, mixtures of these
two LAB with different bacterial genera, including also Streptococcus [87,92], and Enterococcus [7],
were used. With respect to viral agents, the most common viral infections investigated were
RV [6,7,79,89,92], transmissible gastroenteritis coronavirus (TGEV) [7,88], or murine NV [90].
Table 2. Effects of probiotics against digestive viruses.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference












bifidum 2-2, and B. bifidum 3-9
Lactobacilli or
bifidobacteria
(5 × 107 cells/mL) for
24 or 48 h
Enteric common
infectious diseases
Administration of L. rhamnosus
induces the activation of TLR3,
and there is an increase in the
production of IFN-β by bovine
intestinal epithelial cells, which
may have beneficial effects on the
protection against enteric viruses
in vivo
[87]



















Administration of lactic acid
bacteria (LAB) shows a protective
effect against VR and TGEV. In
the case of L. casei, Shirota has a
high level of protection against
TGEV by releasing highly reactive
oxygen species (ROS) into the
TLT cell line. L. plantarum
PCA236 also stimulated the
release of these reactive species
[7]















at a density of
5 × 108 cells/mL for
48 h.
RV
B. infantis MCC12 and B. breve
MCC1274 increased the
production of INF-β in PIE cells,
in response to VR infection. They
also increased the expression of
CXCL10 and IL-6 genes,
especially the B. infantis
[6]
In vitro using PIE cells L. rhamnosus CRL1505 andL. plantarum CRL1506
Lactobacilli
(5 × 108 cells/mL)






PIE cells. The expression of the
IL-15 and RAE1 genes that
mediate poly (I:C) inflammatory
damage was also reduced
[85]
In vivo using pregnant
BALB/c mice B. bifidum G9-1 (BBG9-1)
Orally administration
of 3 × 107 CFU of
BBG9-1, respectively,
once daily for 10 days
from 2 days before to
7 days after RV
infection
RV
The oral administration of B.
bifidum induced mucosal
protective factors, protecting
against RV-induced lesions, and
improving diarrhea. B. bifidum
may be an effective method to
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Table 2. Cont.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference
In vivo using mice
Human-derived Lactobacillus




2 × 109 CFU/mL in
PBS. Mice received
gastric gavages
(50 µL) of probiotics
or vehicle daily from
days 5 to 14 of life.
RV
A decrease in proinflammatory
cytokine concentrations was seen,
including the inflammatory
protein of macrophages-1a and
IL-1b, as well as an increase in the
specific antibodies against
rotavirus after the administration
of the two probiotic strains. L.
reuteri reduced diarrhea episodes
[89]
In vitro in ST cells L. plantarum Probio-38 and L.salivarius Probio-37 10
8 to 109 CFU/mL TGEV
Both strains survived in synthetic
gastric juice and inhibited TGE
coronavirus in vitro in ST cells
[88]
In vivo using 49
children
L. casei subsp. casei strain GG
(LGG), L. casei subsp.
rhamnosus (Lactophilus), or a
combination of S.
thermophilus and L. delbrückii
subsp. bulgaricus (Yalacta®)
Twice daily for 5 days RV
Administration of LGG increased
the cells secreting specific IgA
antibodies to rotavirus and in the
convalescence stage. In addition,
the duration of diarrhea was
reduced in children
[92]
In vivo using 12 mice L. paracasei ATCC 334 108 CFU for 6 days
Murine norovirus
(NV)
Intake of L. paracasei before the
infection by murine NV, reduced
the level of expression of the
mRNA that encodes the viral
polymerase
[90]
Clinical trial in 816
children
L. rhamnosus R0011 and
Lactobacillus helveticus R0052
4 × 109 CFU of
L. rhamnosus and
L. helveticus (95:5 ratio)




No beneficial effects associated
with the administration of
L. rhamnosus and L. helveticus have
been observed; these probiotics
do not reduce the severity of
acute gastroenteritis or expedite
the clearance of viruses in stool
[91]
As can be seen in Table 2, all the probiotic treatments demonstrated different degrees of
protection against viral infections by different mechanisms, such as stimulating interferons,
interleukins of Ig production, or accelerating reactive oxygen species (ROS) depletion in
tissues. In some cases, probiotic strains also benefited the host against viral infection via
genetic regulations modifying the expression of mRNA encoding viral polymerase [90] or
genes involved in the inflammatory response [85].
6. Probiotics against Other Viruses
As was previously defined, there are a large variety of viruses that can cause other
types of infections besides respiratory or digestive infections. Unfortunately, many of
these cause very serious diseases that probiotics, and even in some cases the most modern
medical technologies, cannot solve. However, for viruses that cause hepatitis, skin virus
infections, human immunodeficiency virus (HIV), or HPV, probiotics could directly or
indirectly, help reduce their symptoms or prevent infection
Table 3 shows the probiotic effects on the symptoms of other viral infections that
were performed in mouse models [21,93], monkeys [22], or humans [26,94–100]. The trials
performed investigated the effects of LAB, but also other less frequent species, such as
Enterococcus [94], Escherichia [22], or even yeast, such as Saccharomyces [93]. With respect to
viral infections, these probiotic agents were employed to improve the symptomatology of
viral infections, such as HCV ([93], HPV [21,26,95,96], HIV [22,97,98], or herpes simplex
virus (HSV) type I [22,93].
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Table 3. Effects of probiotics against other viruses.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference





Enterococcus faecalis FK-23 900 mg of E. faecalis3 times daily HCV
E. faecalis decreased
alanine transferase






Clinical trial in 180
women
Lactobacillus rhamnosus GR-1
and Lactobacillus reuteri RC-14
(50% each)
180 mg including 5.4 × 109








smear rates, but it did
not influence the
genital burden of HPV
[26]
Clinical trial in 117
women
L. rhamnosus BMX 54 after a
standard treatment of 500 mg
metronidazole twice a day for
7 days
Vaginal tablets of
104 CFU/tablet one each 3
days for 20 days and then
once every 5 days for 2
months (short treatment),






recreation of the vaginal
balance, and therefore it
can be useful to control
the infection by the
human papilloma virus
[95]
Clinical trial in 54
women Lactobacillus casei Shirota









as high in the probiotic
group
[96]





















level of tryptophan in
plasma and increases
the concentration of
serotonin in the blood
[97]
In vitro trial in Vero
African green monkey
kidney cells
L. rhamnosus PTCC 1637 and









with the virus for










5 groups of 10, treatment
groups were administrated
either orally or
intravenously with 100 µL
B. bifidum (1 × 108 CFU) 5
times at a 4-day interval
for 20 days, including 2
times before and after
tumor induction and one








secretion of INF-y and
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Table 3. Cont.
Type of Study Probiotics Dosage and Time ofExposure Viruses Main Findings Reference
Clinical trial in 65
women with confirmed
HIV infection




with 2 × 109 CFU and
400 mg of oral
metronidazole twice daily











Clinical trial in 14
children L. plantarum 299v
lyophilized powder in an










of CD4+ T cells
[99]
Clinical trial in 39
subjects L. reuteri MM2




detected in either safety
or tolerance parameters
[100]
In vivo using male mice Saccharomyces boulardiiCNCM I-745
Oral gavage with either S.












Regarding hepatitis infections, there are different studies that support the idea of
including probiotics in routine therapy to fight fatigue, nausea, and low appetite, which are
secondary effects of hepatitis C drug treatment [94]. An imbalance in intestinal microbiota
has been seen in individuals with liver cirrhosis. Thus, for this reason, modifying the GM
with probiotic supplements can decrease endotoxins and other compounds derived from
bacteria, such as ethanol, phenol, and indoles, which are toxic and cause liver damage [94].
In HIV prevention, various observational studies have shown probiotic supplementa-
tion can prevent bacterial vaginosis caused by Gardnerella vaginalis and Mycoplasma hominis,
a condition that facilitates the transmission of HIV [98]. Gori et al. [101] showed that in
HIV-positive patients, there is usually a gastrointestinal deterrent at the beginning of the
disease. This symptom is associated with, among other things, the GM disorders, which
confirms a possible correlation between GM, gastrointestinal mucosal damage, and the
immune system [102]. In HIV-positive people, there occurs an alteration of total microbial
colonization as well as the microbiota composition in the oral cavity, and decreased CD4+
T cell counts have been associated with the presence of oral lesions [102]. Additionally, an
intestinal disorder with pro-inflammatory effects has often been seen [97] with the increase
in GM of either pro-inflammatory or potentially pathogenic bacterial populations, such
as Pseudomonas aeruginosa and Candida albicans, whereas there is a reduction in beneficial
bacterial counts such as Bifidobacterium and Lactobacillus [102]. An elegant review recently
reported [103] investigated the effects of probiotics on inflammation markers in HIV pa-
tients, with no clear results due to the generally limited power of the studies included, that
in most cases must be considered only exploratory.
Other authors reported that the prevailing HIV-associated dysbiosis across several
cohorts seems to consist of enrichment of the phylum Proteobacteria including several
subtaxa containing pathogenic bacteria, combined with a depletion of taxa within the
bacterial families Ruminococcaea and Lachnospiracea, known producers of SCFA [103]. A
modification of the activity of the enzyme indoleamine 2,3-dioxygenase 1 induced by
the interferon has also been described, which produces alterations in the tryptophan
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metabolism pathway [97]. These findings support the hypothesis that alterations in the
gastrointestinal tract are a very important factor in the pathogenesis of HIV infection. In a
study by Sheri et al. [97], it was shown that a mixture of probiotics, combined with IL-21,
reduced the expression of several markers that activate CD4+ T cells. Because of this, it
was suggested that probiotics act on the signaling of toll-like receptors (TLRs). Another
important factor in the use of probiotics among HIV patients is that GM is crucial for the
normal development of gut-associated lymphoid tissue (GALT), essential to ensure an
appropriate immune activity [102].
However, the use of probiotics in severe immunocompromised or severely debilitated
patients, such as HIV or recently transplanted patients [104]. HIV infection, at least during
later stages, is associated with increased gut permeability and loss of local host immunity
in GALT that may predispose to invasive infections. Thus, it was previously identified at
least 11 single cases of patients, who after Lactobacillus supplementation suffered invasive
Lactobacillus infections, causing symptoms such as bacteremia, pneumonia, or empyema,
and even causing one documented death [104]. The risk of probiotics in immunocompro-
mised people varies based on their contents, being L. rhamnosus the riskiest Lactobacillus
species [105].
The idea of oral administration of probiotics against vaginal infections came from the
knowledge that many urogenital infections arise from the entrance of a pathogen from
the rectum to the perianal skin and then the vagina [106]. The mechanisms of action of
probiotics at vaginal level include acidification of the mucosal surface, prevention of the
adherence of pathogens, production of substances such as vitamins an immune modulators,
and synergistic action with the host immune system [106]. Palma et al. [95] reported that
HPV clearance was higher with the treatment of metronidazole and six months vaginal
Lactobacillus implementation. On the other hand, Verhoeven et al. [96] previously failed
to find any influence of probiotics on HPV clearance in a group of women with HPV-
related low-grade squamous intraepithelial lesion using oral Lactobacillus casei Shirota
(1 × 1010 CFU/day) for six months.
7. Conclusions
Recently published studies show the beneficial effects of using various probiotics
to treat different diseases caused by viruses. Although they do not cure diseases, these
probiotics are beneficial to patients because, in some cases, they improve the immune
system and reduce the number of days of illness and the symptoms of the disease. Given
the results obtained, probiotics can be an alternative for the prevention and treatment of
many viral diseases that cause so many deaths around the world each year, or at least
improve the quality of life of patients suffering from these diseases. Especially, there is
great potential for probiotics consumed through functional foods, that seen to show better
consumer acceptance than pharmacological presentations. There is a profound need for
more in-depth studies into the benefits of the administration of probiotics in viral infections.
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